600201 logo

Jinyu Bio-technology Co., Ltd. Stock Price

SHSE:600201 Community·CN¥15.7b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

600201 Share Price Performance

CN¥0
-6.85 (-100.00%)
CN¥0
-6.85 (-100.00%)
Price CN¥0

600201 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Adequate balance sheet with moderate growth potential.

2 Risks
1 Reward

Jinyu Bio-technology Co., Ltd. Key Details

CN¥1.3b

Revenue

CN¥652.7m

Cost of Revenue

CN¥674.4m

Gross Profit

CN¥573.6m

Other Expenses

CN¥100.8m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Apr 23, 2026
0.092
50.82%
7.59%
0.3%
View Full Analysis

About 600201

Founded
1992
Employees
1740
CEO
Jing Zhang
WebsiteView website
www.jinyu.com.cn

Jinyu Bio-technology Co., Ltd. manufacturing and sales of veterinary biological drugs in China. The company operates through three segments, such as veterinary biological products, veterinary chemical drugs, and traditional Chinese veterinary medicines. The company offers various pig vaccines, including combined porcine circovirus type 2 and mycoplasma pneumoniae, classical swine fever, combined transmissible gastroenteritis and porcine epidemic diarrhea, swine influenza bivalent, porcine reproductive and respiratory syndrome, pseudorabies thermo-stable, porcine reproductive and respiratory syndrome virus, porcine circovirus type 2 baculovirus vector, combined transmissible gastroenteritis and porcine epidemic diarrhea, swine foot and mouth disease bivalent, porcine parvovirus, pseudorabies, haemophilus parasuis trivalent, and porcine circovirus type 2 vaccines. It also provides ruminant vaccines, such as foot and mouth disease trivalent, bovine pasteurella multocida, combined bovine viral diarrhea disease and infectious bovine rhinotracheitis, brucella gene deletion, goat pox, brucellosi, brucellosis, foot and mouth disease bivalent and type O, clostridium chauvoei, lumpy skin disease, combined ovine infectious necrotic hepatitis and braxy, and caprine infectious pleuropneumonia, as well as combined ovine braxy, struck, lamb dysentery, enterotoxaemia, and black disease and clostridium botulinum toxonosis vaccines. In addition, the company offers avian vaccines; rabies vaccines; and PCR and Elisa diagnostic kits. Further, it is involved in manufacturing and sales of veterinary chemical preparations, chemical reagents and auxiliary agents, biological drug preparations, and advanced medical equipment and instruments; biotechnology development, transfer, and consulting services; import and export of goods and technology; and provision of property management services. The company was founded in 1992 and is headquartered in Hohhot, China.

Recent 600201 News & Updates

Recent updates

No updates